Detalhe da pesquisa
1.
Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer.
N Engl J Med
; 381(2): 121-131, 2019 07 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-31157964
2.
Cancer Molecular Screening and Therapeutics (MoST): a framework for multiple, parallel signal-seeking studies of targeted therapies for rare and neglected cancers.
Med J Aust
; 209(8): 354-355, 2018 10 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-30138578
3.
Long-Term Effectiveness and Safety of Pravastatin in Patients With Coronary Heart Disease: Sixteen Years of Follow-Up of the LIPID Study.
Circulation
; 133(19): 1851-60, 2016 May 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-27016105
4.
Health-Related Quality of Life in Metastatic, Hormone-Sensitive Prostate Cancer: ENZAMET (ANZUP 1304), an International, Randomized Phase III Trial Led by ANZUP.
J Clin Oncol
; 40(8): 837-846, 2022 03 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34928708
5.
Overall Survival of Men with Metachronous Metastatic Hormone-sensitive Prostate Cancer Treated with Enzalutamide and Androgen Deprivation Therapy.
Eur Urol
; 80(3): 275-279, 2021 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-34030924
6.
Recruitment to randomised studies.
Med J Aust
; 178(11): 579-81, 2003 Jun 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-12765509